Sorted By:

Relevance


Real Change for Patients with GI Cancer

PhRMA  |  Blog Post

Our hope is that this will help raise awareness for GI cancers and spur conversation that will result in continued progress.
http://catalyst.phrma.org/real-change-for-patients-with-gi-cancer

Medicare Monday: Another example of the competitive market at work in Part D

PhRMA  |  Blog Post

Visit PhRMA.org/PartD to learn more about how Medicare Part D helps ensure that patients have affordable access to needed prescription medications.
http://catalyst.phrma.org/medicare-monday-another-example-of-the-competitive-market-at-work-in-part-d

High Cholesterol Patient Profile - Betty

PhRMA  |  Graphic

...
https://www.phrma.org/graphic/high-cholesterol-patient-profile-betty

High Coinsurance on Specialty Tiers

PhRMA  |  Graphic

...
https://www.phrma.org/graphic/high-coinsurance-on-specialty-tiers

Costs and Consequences of Not Treating High Cholesterol

PhRMA  |  Blog Post

High cholesterol is treatable for many patients and, with greater treatment rates and continued innovation, we can reduce the economic and societal impact of heart disease, and help patients live longer, healthier lives.
http://catalyst.phrma.org/costs-and-consequences-of-not-treating-high-cholesterol

New Video: How Medicines Can Curb Health Care Costs

PhRMA  |  Blog Post

Medicines can continue to save lives and be part of the solution to reducing medical spending, but only if we have a health care system that supports innovation and encourages the development of new treatments for Alzheimer’s disease and other costly conditions.
http://catalyst.phrma.org/new-video-how-medicines-can-curb-health-care-costs

SB 17 doesn’t address pressing prescription drug transparency issues for CA voters

PhRMA  |  Blog Post

PhRMA has convened a national conversation tackling this complex issue, exploring medicine cost trends, the rising cost of chronic disease, insurance coverage of medicine, the role of middlemen and what our industry can do to make medicine more affordable for patients.
http://catalyst.phrma.org/sb-17-doesnt-address-most-pressing-prescription-drug-transparency-issues-for-california-voters

Share the Savings - Why is a visit to the pharmacy different?

PhRMA  |  Graphic

   ...
https://www.phrma.org/graphic/share-the-savings-why-is-a-visit-to-the-pharmacy-different

Medicines in Development for Arthritis 2014 Report

PhRMA  |  Report

Approximately 15 million adults report that they are unable to perform some common activities due to the pain; 10 for osteoarthritis, the most com-mon form of arthritis, which affects nearly 27 million Americans; and 7 for psoriatic arthritis, an in?
https://www.phrma.org/report/medicines-in-development-for-arthritis-2014-report

Medicines in Development for Infectious Diseases 2013 Report

PhRMA  |  Report

Recently, some infectious pathogens, such as pseudomonas bacteria, have become resistant to available treatments.
https://www.phrma.org

340B Spotlight: ICYMI – AJC looks at how some Georgia hospitals are profiting off 340B

PhRMA  |  Blog Post

It’s long past time for the 340B program to evolve.
http://catalyst.phrma.org/340b-spotlight-icymi-ajc-looks-at-how-some-georgia-hospitals-are-profiting-off-340b

Medicines in Development for Vaccines 2017 Update

PhRMA  |  Report

These include 137 for infectious diseases, 101 for cancer, 10 for allergies, eight for autoimmune disease, four for Alzheimer’s disease and five for other diseases.
https://www.phrma.org/vaccines-2017-report

New Study on HTA Processes Highlights Areas for Improvement to Accelerate Patients’ Access to Innovative Medicines

PhRMA  |  Press Release

The report sets the foundation for a regular exercise, which will receive continuous support from the four trade associations.
https://www.phrma.org/press-release/new-study-on-hta-processes-highlights-areas-for-improvement-to-accelerate-patients-access-to-innovative-medicines

More Than 200 Innovative Medicines in Development For Heart Disease and Stroke

PhRMA  |  Press Release

Since 2000, PhRMA member companies have invested approximately $550 billion in the search for new treatments and cures, including an estimated $48.5 billion in 2012 alone.
https://www.phrma.org/press-release/more-than-200-innovative-medicines-in-development-for-heart-disease-and-stroke

More Than 240 Innovative Medicines in Development For Leukemia, Lymphoma and Other Blood Cancers

PhRMA  |  Press Release

Since 2000, PhRMA member companies have invested approximately $550 billion in the search for new treatments and cures, including an estimated $48.5 billion in 2012 alone.
https://www.phrma.org/press-release/more-than-240-innovative-medicines-in-development-for-leukemia-lymphoma-and-other-blood-cancers

Power of Medicines: Saving Lives and Building the Future

PhRMA  |  Video

Therapeutic advances have also transformed treatment of rheumatoid arthritis.
https://www.phrma.org/video/the-power-of-medicines-saving-lives-and-building-for-the-future

New PhRMA report: More than 170 medicines in development for diabetes offer patients longer, healthier lives

PhRMA  |  Blog Post

Bill Chin, where he tells the story of diagnosing his son with type 1 diabetes and how his family and his professional career have both informed his perspective on the disease.
http://catalyst.phrma.org/new-phrma-report-more-than-170-medicines-in-development-for-diabetes-offer-patients-longer-healthier-lives

Medicines in Development for Older Americans 2013 Report

PhRMA  |  Report

Today nearly 92 percent of older adults have at least one chronic condition, and 77 percent have at least two, according to the National Council on Aging (NCOA).
https://www.phrma.org

New Hope for Patients with Hepatitis C

PhRMA  |  Graphic

...
https://www.phrma.org/graphic/new-hope-for-patients-with-hepatitis-c

Sir Andrew Witty

PhRMA  |  Biography

Andrew has a Joint Honours BA in Economics from the University of Nottingham.
https://www.phrma.org/biography/sir-andrew-witty

ICYMI: New report outlines steps for greater transparency in health care

PhRMA  |  Blog Post

As our health care system continues to evolve, it is important to ensure that consumers have access to the right tools at the right time when making important decisions regarding their care.
http://catalyst.phrma.org/icymi-new-report-outlines-steps-for-greater-transparency-in-health-care

4 recommendations for ICER

PhRMA  |  Blog Post

Implementation of a fully transparent process in which ICER meaningfully engages with stakeholders, including stakeholders with disease-specific expertise, in setting priorities for assessment and developing its evidence reports.
http://catalyst.phrma.org/4-recommendations-for-icer

Improved Quality of Life for Rheumatoid Arthritis Patients

PhRMA  |  Graphic

...
https://www.phrma.org/graphic/improved-quality-of-life-for-rheumatoid-arthritis-patients

How 340B discounts work

PhRMA  |  Blog Post

Learn more about 340B at PhRMA.org/340B and stay tuned to 340B Spotlight posts for more on this important program and the changes needed to ensure it benefits those it was intended to help.
http://catalyst.phrma.org/how-340b-discounts-work

High Cholesterol Patient Profile - Bill

PhRMA  |  Graphic

...
https://www.phrma.org/graphic/high-cholesterol-patient-profile-bill

You have reviewed the first 225 results out of 2564. Each page contains 25 results. You're on page 9.

prev 7 8 9 10 11 12 next